Συν-νοσηρότητα και Covid-19 σε Ευρωπαίους ηλικίας 50 ετών και άνω
Comorbidity and Covid-19 among Europeans aged 50 or higher
View/ Open
Keywords
Συννοσυρότητα ; COVID-19 ; Πολυνοσυρότητα ; Ευρωπαίοι ; Χώρες ; Ηλικία ; Έμφραγμα ; Καρκίνος ; Αναπνευστικά προβλήματα ; Υψηλή αρτηριακή πίεση ; Παχυσαρκία ; Λογιστική παλινδρόμηση ; Μοντέλα ; Εμβόλια ; Κύμα COVID-19 ; Θετικό test COVID-19 ; ΝοσηλευόμενοιAbstract
The impact of comorbidities on the outcomes of COVID-19 has been recognized since
the early days of the pandemic. However, establishing causality and determining
underlying mechanisms and clinical consequences has been difficult—due to the
multitude of confounding factors and patient variability. Several distinct pathological
mechanisms, which are not active in every patient, determine health outcomes in the
three different phases of COVID-19—from the initial phase of viral replication to
inflammatory lung damage and post-acute sequelae. Specific comorbidities (and overall
multimorbidity) can either exacerbate these pathological mechanisms or reduce the
patient's tolerance to organ injury.
In conclusion, comorbidity plays an important role in shaping the outcomes of COVID 19 in Europeans aged 50 years and older. The presence of comorbidities increases the
risk of severe disease and mortality in this population. Effective management of
comorbidity and COVID-19 requires a multidimensional approach that includes
prevention, vaccination, integrated care, and addressing health care access and health
literacy. By understanding the relationship between comorbidity and COVID-19,
healthcare systems can develop targeted strategies to protect and support individuals in
this vulnerable age group.